<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02567071</url>
  </required_header>
  <id_info>
    <org_study_id>C14-70</org_study_id>
    <secondary_id>2015-A00586-43</secondary_id>
    <nct_id>NCT02567071</nct_id>
  </id_info>
  <brief_title>Natural Microbiota Restoration After C-section Birth</brief_title>
  <acronym>RESTORE</acronym>
  <official_title>Retablissement Du Microbiote Naturel Apres Naissance Par Cesarienne</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proportion of cesarean deliveries reached 30% of births in the US in 2008, while in the&#xD;
      1970s, it rarely reached 15%, as recommended by WHO. According to recent reports in some&#xD;
      hospitals in China the use of cesarean section increased from 5% in the 1970s to over 60%.&#xD;
      The use of C-section continues to grow in every countries of the world despite that current&#xD;
      knowledge leads us to think that the vaginal birth, retained through millennia during&#xD;
      mammalian evolution, guarantees the implementation of the best suited intestinal microbiota&#xD;
      to build immunity and beneficial protective functions under the balanced mutual association&#xD;
      between the host and its microbiota. Oral administration of a previously impregnated swab, by&#xD;
      vaginal and maternal perineal secretions, following birth by planned C-section, would restore&#xD;
      the normal development of the newborn intestinal microbiota mimicking exposure to these&#xD;
      secretions during vaginal delivery.&#xD;
&#xD;
      The expected benefit is the establishment of a rich and diverse microbiota in individuals in&#xD;
      the intervention group and by extension improving the overall health of these individuals.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 6, 2016</start_date>
  <completion_date type="Actual">April 2019</completion_date>
  <primary_completion_date type="Actual">April 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diversity of the intestinal microbiota</measure>
    <time_frame>1 year</time_frame>
    <description>Intestinal microbiota diversity will be evluated through metagenomics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Health status</measure>
    <time_frame>1 year</time_frame>
    <description>Health status of the newborn will be evaluated through questionnaries.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Insufficient Intestinal Microbiota Diversity After C-section Birth</condition>
  <arm_group>
    <arm_group_label>Intervention Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>75 children born by planned C-section will be exposed to the perineal microbiota of their mothers through perineal impregnated swab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>75 children born by planned C-section will be exposed to clean swab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>75 children born vaginally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>perineal impregnated swab</intervention_name>
    <description>After planned C-section birth, newborns will suck on previously impregnated swab by perineal and vaginal mother secretions.</description>
    <arm_group_label>Intervention Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>clean swab</intervention_name>
    <description>After planned C-section birth, newborns will suck on clean swab.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  over the age of legal majority&#xD;
&#xD;
          -  delivery by planned C-section at term or vaginal delivery at term&#xD;
&#xD;
          -  registered at a social security service&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV or other STD patients&#xD;
&#xD;
          -  immunocompromised patients&#xD;
&#xD;
          -  known streptococcus B carriers&#xD;
&#xD;
          -  known vaginal or perineal herpes infections&#xD;
&#xD;
          -  chronic disease patients (obesity, diabetes, IBD)&#xD;
&#xD;
          -  IMC before pregnancy &gt; 30 kg/m²&#xD;
&#xD;
          -  antibiotic treatments one month before delivery&#xD;
&#xD;
          -  emergency C-section&#xD;
&#xD;
          -  Premature delivery (&lt;37 amenorrhea weeks)&#xD;
&#xD;
          -  hospitalized for more than one week before delivery&#xD;
&#xD;
          -  known HVC infections&#xD;
&#xD;
          -  for the newborns: every diagnosed anomaly&#xD;
&#xD;
          -  patients who do not understand the research procedures or those that are&#xD;
             institutionalized, or those unable to give informed consent&#xD;
&#xD;
          -  patients deprived of ther liberty by legal or administrative decisions&#xD;
&#xD;
          -  patients under an exclusion period from another study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacky Nizard, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Gynécologie-Obstétrique, Groupe Hospitalier Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 15, 2015</study_first_submitted>
  <study_first_submitted_qc>September 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2015</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>C-section</keyword>
  <keyword>Microbiota</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

